NM_002473.6:c.5026A>G
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 1P and 9B. PP2BP6BS1BS2
The NM_002473.6(MYH9):āc.5026A>Gā(p.Lys1676Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000546 in 1,613,138 control chromosomes in the GnomAD database, including 1 homozygotes. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_002473.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYH9 | NM_002473.6 | c.5026A>G | p.Lys1676Glu | missense_variant | Exon 35 of 41 | ENST00000216181.11 | NP_002464.1 | |
MIR6819 | NR_106877.1 | n.*94A>G | downstream_gene_variant | |||||
MIR6819 | unassigned_transcript_3662 | n.*94A>G | downstream_gene_variant | |||||
MIR6819 | unassigned_transcript_3663 | n.*128A>G | downstream_gene_variant |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000434 AC: 66AN: 152220Hom.: 1 Cov.: 33
GnomAD3 exomes AF: 0.000331 AC: 83AN: 250738Hom.: 0 AF XY: 0.000339 AC XY: 46AN XY: 135562
GnomAD4 exome AF: 0.000557 AC: 814AN: 1460918Hom.: 0 Cov.: 32 AF XY: 0.000556 AC XY: 404AN XY: 726782
GnomAD4 genome AF: 0.000434 AC: 66AN: 152220Hom.: 1 Cov.: 33 AF XY: 0.000350 AC XY: 26AN XY: 74364
ClinVar
Submissions by phenotype
not provided Benign:3
- -
MYH9: PP2, BS2 -
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
not specified Uncertain:2
Variant summary: MYH9 c.5026A>G (p.Lys1676Glu) results in a conservative amino acid change located in the myosin tail domain (IPR002928) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00033 in 250738 control chromosomes (gnomAD). To our knowledge, no occurrence of c.5026A>G in individuals affected with Macrothrombocytopenia And Granulocyte Inclusions With Or Without Nephritis Or Sensorineural Hearing Loss and no experimental evidence demonstrating its impact on protein function have been reported. Six submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as uncertain significance. -
The Lys1676Glu variant in MYH9 has not been reported in individuals affected wit h hearing loss, but has been identified in 0.1% (8/8600) of European American ch romosomes in a broad population by the NHLBI Exome sequencing project (http://ev s.gs.washington.edu/EVS/; dbSNP rs138158369). Although this variant has been see n in the general population, a pathogenic role cannot be ruled out due to variab le expressivity and onset of hearing loss associated with MYH9 variants (Pecci 2 008). Computational analyses (biochemical amino acid properties, conservation, A lignGVGD, PolyPhen2, and SIFT) do not provide strong support for or against an i mpact to the protein. In summary, additional data is needed to determine the cli nical significance of this variant. -
MYH9-related disorder Benign:2
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Autosomal dominant nonsyndromic hearing loss 17 Benign:1
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. -
Hearing impairment Benign:1
PP3_Supporting, BS1_Strong, BS2_Strong -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at